세계의 후천성 희귀 혈액질환 시장 : 북미가 세계 시장의 3분의 1을 넘는 점유율을 차지

Report Scope:

The latest market report by Persistence Market Research on the global acquired orphan blood disease market evaluates the opportunities and current market scenario, providing insights and updates about corresponding segments involved in the market for the forecast period of 2022-2032. The report provides a detailed assessment of key market dynamics and comprehensive information about the structure of the market. This study contains detailed insights into how the market is anticipated to grow during the forecast period of 2022-2032.

The primary objective of the report is to provide insights regarding opportunities in the market that are supporting the transformation of global businesses associated with an acquired orphan blood disease. It is very important to consider that, in an ever-wavering economy, we provide estimated (Y-o-Y) year-on-year growth rate in addition to the compound annual growth rate (CAGR) for overall forecasts, to enable readers better understand the analysis and evaluation of the market, and to discover lucrative opportunities in this space.

This report also provides an estimate of market size and corresponding revenue forecasts carried out in terms of absolute $ opportunity. It also offers actionable insights based on future trends in the market. Furthermore, new and emerging players in the global acquired orphan blood disease market can make use of the information presented in the study for effective business decisions, which will provide momentum to their businesses as well as the global market.

The study is relevant for manufacturers, suppliers, distributors, and investors in the acquired orphan blood disease market. All stakeholders, as well as industry experts, researchers, journalists, and business researchers can leverage the information and data represented in the report.

Key Market Segments

Persistence Market Research's report on the global acquired orphan blood disease market offers information divided into four segments - therapy, disease indication, distribution channel, and region.

Therapy

Recombinant Factor

Immunoglobulin Infusion Therapy

Activated Prothrombin Complex Concentrate

Thrombopoietin Receptor Agonists

Others

Disease Indication

Acquired Agranulocytosis

Acquired Hemophilia

Acquired Von Willebrand Syndrome

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Myelodysplastic Syndrome

Other

Distribution Channel

Hospital Pharmacy

Retail Pharmacy

Others

Region

North America

Europe

Latin America

East Asia

The Middle East & Africa

South Asia & Pacific

Key Questions Answered in Study

Which region will hold the highest market share over the forecast period?

Which region is experiencing the highest growth (CAGR)?

Which factors are impacting the global acquired orphan blood disease industry?

What are the global trends impacting the market?

What strategies must emerge players adopt to capture opportunities in various regions in the market?

What is the structure of the global acquired orphan blood disease market?

Research Methodology

Persistence Market Research is committed to providing unbiased market research solutions to its clients. The company follows a robust methodology for the deduction of data included in this report. A unique research methodology is utilized to conduct extensive research on the global acquired orphan blood disease market, and reach conclusions about the future growth factors of the market. The research methodology comprises primary research methods coupled with secondary research methods, which ensures the accuracy and reliability of the conclusions in this report.

A demand-side approach is followed to estimate the sales of target products, followed by an in-depth supply-side assessment of value generated, key trends, and events over a predefined period.

This methodology is based on standard market structures, methods, and definitions that are based on inputs from local sources in over six regions - North America, Latin America, Europe, South Asia and Pacific, East Asia, and the Middle East & Africa, which Persistence Market Research considers for segmenting the global market. Statistics, characteristics, and variances are collected at a regional level, aggregated at the same level, and then synthesized at a worldwide level, to create global market measurements.

Our main sources of research include:

Primary Research

Secondary Research

Trade Research

Social Media Research

Table of Contents

1. Executive Summary

• 1.1. Global Market Outlook
• 1.2. Demand Side Trends
• 1.3. Supply Side Trends
• 1.4. Technology Roadmap
• 1.5. Analysis and Recommendations

2. Market Overview

• 2.1. Market Coverage / Taxonomy
• 2.2. Market Definition / Scope / Limitations

3. Key Market Trends

• 3.1. Key Trends Impacting the Market
• 3.2. Product Innovation / Development Trends

4. Key Success Factors

• 4.1. Product Adoption / Usage Analysis
• 4.2. Product USPs / Features
• 4.3. Strategic Promotional Strategies

5. Global Acquired Orphan Blood Disease Market Demand Analysis 2017-2021 and Forecast, 2022-2032

• 5.1. Historical Market Volume (Tons) Analysis, 2017-2021
• 5.2. Current and Future Market Volume (Tons) Projections, 2022-2032
• 5.3. Y-o-Y Growth Trend Analysis

6. Global Acquired Orphan Blood Disease Market - Pricing Analysis

• 6.1. Regional Pricing Analysis By Therapy
• 6.2. Global Average Pricing Analysis Benchmark

7. Global Acquired Orphan Blood Disease Market Demand (in Value or Size in US$ Mn) Analysis 2017-2021 and Forecast, 2022-2032

• 7.1. Historical Market Value (US$ Mn) Analysis, 2017-2021
• 7.2. Current and Future Market Value (US$ Mn) Projections, 2022-2032
  • 7.2.1. Y-o-Y Growth Trend Analysis
  • 7.2.2. Absolute $ Opportunity Analysis

8. Market Background

• 8.1. Macro-Economic Factors
  • 8.1.1. Global GDP Growth Outlook
  • 8.1.2. Global Industry Value Added Overview
  • 8.1.3. Global Infrastructure Investment Overview
  • 8.1.4. Global Construction Spending Analysis
  • 8.1.5. Other Macro Economic Factors
• 8.2. Forecast Factors - Relevance & Impact
  • 8.2.1. Top Companies Historical Growth
  • 8.2.2. GDP Growth forecast
  • 8.2.3. Construction Industry forecast
  • 8.2.4. Distribution Channel Growth Outlook
  • 8.2.5. Collaboration Activities
• 8.3. Value Chain
  • 8.3.1. Raw Material Suppliers
  • 8.3.2. List of Manufacturers
  • 8.3.3. List of Distributors
• 8.4. COVID-19 Crisis - Impact Assessment
  • 8.4.1. Current Statistics
  • 8.4.2. Short-Mid-Long Term Outlook
  • 8.4.3. Likely Rebound
• 8.5. Market Dynamics
  • 8.5.1. Drivers
  • 8.5.2. Restraints
  • 8.5.3. Opportunity Analysis
  • 8.5.4. Trends

9. Global Acquired Orphan Blood Disease Market Analysis 2017-2021 and Forecast 2022-2032, by Therapy

• 9.1. Introduction / Key Findings
• 9.2. Historical Market Size (US$ Mn) and Volume Analysis by Type, 2017-2021
• 9.3. Current and Future Market Size (US$ Mn) and Volume Analysis and Forecast by Therapy 2022-2032
  • 9.3.1. Recombinant Factor
  • 9.3.2. Immunoglobulin Infusion Therapy
  • 9.3.3. Activated Prothrombin Complex Concentrate
  • 9.3.4. Thrombopoietin Receptor Agonists
  • 9.3.5. Others
• 9.4. Market Attractiveness Analysis by Therapy

10. Global Acquired Orphan Blood Disease Market Analysis 2017-2021 and Forecast 2022-2032, By Disease Indication

• 10.1. Introduction / Key Findings
• 10.2. Historical Market Size (US$ Mn) and Volume Analysis By Disease Indication, 2017-2021
• 10.3. Current and Future Market Size (US$ Mn) and Volume Analysis and Forecast By Disease Indication, 2022-2032
  • 10.3.1. Acquired Agranulocytosis
  • 10.3.2. Acquired Hemophilia
  • 10.3.3. Acquired Von Willebrand Syndrome
  • 10.3.4. Paroxysmal Nocturnal Hemoglobinuria (PNH)
  • 10.3.5. Myelodysplastic Syndrome
  • 10.3.6. Others
• 10.4. Market Attractiveness Analysis By Disease Indication

11. Global Acquired Orphan Blood Disease Market Analysis 2017-2021 and Forecast 2022-2032, By Distribution Channel

• 11.1. Introduction / Key Findings
• 11.2. Historical Market Size (US$ Mn) and Volume Analysis By Distribution Channel, 2017-2021
• 11.3. Current and Future Market Size (US$ Mn) and Volume Analysis and Forecast By Distribution Channel 2022-2032
  • 11.3.1. Hospital Pharmacy
  • 11.3.2. Retail Pharmacy
  • 11.3.3. Others
• 11.4. Market Attractiveness Analysis By Distribution Channel

12. Global Acquired Orphan Blood Disease Market Analysis 2017-2021 and Forecast 2022-2032, by Region

• 12.1. Introduction
• 12.2. Historical Market Size (US$ Mn) and Volume Analysis by Region, 2017-2021
• 12.3. Current Market Size (US$ Mn) and Volume Analysis and Forecast by Region, 2022-2032
  • 12.3.1. North America
  • 12.3.2. Latin America
  • 12.3.3. Europe
  • 12.3.4. East Asia
  • 12.3.5. South Asia and Pacific
  • 12.3.6. Middle East and Africa (MEA)
• 12.4. Market Attractiveness Analysis By Region

13. North America Acquired Orphan Blood Disease Market Analysis 2017-2021 and Forecast 2022-2032

• 13.1. Introduction
• 13.2. Pricing Analysis
• 13.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017-2021
• 13.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032
  • 13.4.1. By Country
    • 13.4.1.1. U.S.
    • 13.4.1.2. Canada
  • 13.4.2. By Type
  • 13.4.3. By Disease Indication
  • 13.4.4. By Distribution Channel
• 13.5. Market Attractiveness Analysis
  • 13.5.1. By Country
  • 13.5.2. By Type
  • 13.5.3. By Disease Indication
  • 13.5.4. By Distribution Channel
• 13.6. Market Trends
• 13.7. Key Market Participants - Intensity Mapping
• 13.8. Drivers and Restraints - Impact Analysis

14. Latin America Acquired Orphan Blood Disease Market Analysis 2017-2021 and Forecast 2022-2032

• 14.1. Introduction
• 14.2. Pricing Analysis
• 14.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017-2021
• 14.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032
  • 14.4.1. By Country
    • 14.4.1.1. Brazil
    • 14.4.1.2. Mexico
    • 14.4.1.3. Rest of Latin America
  • 14.4.2. By Type
  • 14.4.3. By Disease Indication
  • 14.4.4. By Distribution Channel
• 14.5. Market Attractiveness Analysis
  • 14.5.1. By Country
  • 14.5.2. By Type
  • 14.5.3. By Disease Indication
  • 14.5.4. By Distribution Channel
• 14.6. Market Trends
• 14.7. Key Market Participants - Intensity Mapping
• 14.8. Drivers and Restraints - Impact Analysis

15. Europe Acquired Orphan Blood Disease Market Analysis 2017-2021 and Forecast 2022-2032

• 15.1. Introduction
• 15.2. Pricing Analysis
• 15.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017-2021
• 15.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032
  • 15.4.1. By Country
    • 15.4.1.1. Germany
    • 15.4.1.2. Italy
    • 15.4.1.3. France
    • 15.4.1.4. U.K.
    • 15.4.1.5. Spain
    • 15.4.1.6. BENELUX
    • 15.4.1.7. Russia
    • 15.4.1.8. Rest of Europe
  • 15.4.2. By Type
  • 15.4.3. By Disease Indication
  • 15.4.4. By Distribution Channel
• 15.5. Market Attractiveness Analysis
  • 15.5.1. By Country
  • 15.5.2. By Type
  • 15.5.3. By Disease Indication
  • 15.5.4. By Distribution Channel
• 15.6. Market Trends
• 15.7. Key Market Participants - Intensity Mapping
• 15.8. Drivers and Restraints - Impact Analysis

16. South Asia and Pacific Acquired Orphan Blood Disease Market Analysis 2017-2021 and Forecast 2022-2032

• 16.1. Introduction
• 16.2. Pricing Analysis
• 16.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017-2021
• 16.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032
  • 16.4.1. By Country
    • 16.4.1.1. India
    • 16.4.1.2. ASEAN
    • 16.4.1.3. Oceania
    • 16.4.1.4. Rest of South Asia & Pacific
  • 16.4.2. By Type
  • 16.4.3. By Disease Indication
  • 16.4.4. By Distribution Channel
• 16.5. Market Attractiveness Analysis
  • 16.5.1. By Country
  • 16.5.2. By Type
  • 16.5.3. By Disease Indication
  • 16.5.4. By Distribution Channel
• 16.6. Market Trends
• 16.7. Key Market Participants - Intensity Mapping
• 16.8. Drivers and Restraints - Impact Analysis

17. East Asia Acquired Orphan Blood Disease Market Analysis 2017-2021 and Forecast 2022-2032

• 17.1. Introduction
• 17.2. Pricing Analysis
• 17.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017-2021
• 17.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032
  • 17.4.1. By Country
    • 17.4.1.1. China
    • 17.4.1.2. Japan
    • 17.4.1.3. South Korea
  • 17.4.2. By Type
  • 17.4.3. By Disease Indication
  • 17.4.4. By Distribution Channel
• 17.5. Market Attractiveness Analysis
  • 17.5.1. By Country
  • 17.5.2. By Type
  • 17.5.3. By Disease Indication
  • 17.5.4. By Distribution Channel
• 17.6. Market Trends
• 17.7. Key Market Participants - Intensity Mapping
• 17.8. Drivers and Restraints - Impact Analysis

18. Middle East and Africa Acquired Orphan Blood Disease Market Analysis 2017-2021 and Forecast 2022-2032

• 18.1. Introduction
• 18.2. Pricing Analysis
• 18.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017-2021
• 18.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032
  • 18.4.1. By Country
    • 18.4.1.1. GCC Countries
    • 18.4.1.2. Turkey
    • 18.4.1.3. Northern Africa
    • 18.4.1.4. South Africa
    • 18.4.1.5. Rest of Middle East and Africa
  • 18.4.2. By Type
  • 18.4.3. By Disease Indication
  • 18.4.4. By Distribution Channel
• 18.5. Market Attractiveness Analysis
  • 18.5.1. By Country
  • 18.5.2. By Type
  • 18.5.3. By Disease Indication
  • 18.5.4. By Distribution Channel
• 18.6. Market Trends
• 18.7. Key Market Participants - Intensity Mapping
• 18.8. Drivers and Restraints - Impact Analysis

19. Emerging Countries Acquired Orphan Blood Disease Market Analysis

• 19.1. Introduction
  • 19.1.1. Market Value Proportion Analysis, By Key Countries
  • 19.1.2. Global Vs. Country Growth Comparison
• 19.2. U.S. Acquired Orphan Blood Disease Market Analysis
  • 19.2.1. By Type
  • 19.2.2. By Disease Indication
  • 19.2.3. By Distribution Channel
• 19.3. Canada Acquired Orphan Blood Disease Market Analysis
  • 19.3.1. By Type
  • 19.3.2. By Disease Indication
  • 19.3.3. By Distribution Channel
• 19.4. Mexico Acquired Orphan Blood Disease Market Analysis
  • 19.4.1. By Type
  • 19.4.2. By Disease Indication
  • 19.4.3. By Distribution Channel
• 19.5. Brazil Acquired Orphan Blood Disease Market Analysis
  • 19.5.1. By Type
  • 19.5.2. By Disease Indication
  • 19.5.3. By Distribution Channel
• 19.6. Germany Acquired Orphan Blood Disease Market Analysis
  • 19.6.1. By Type
  • 19.6.2. By Disease Indication
  • 19.6.3. By Distribution Channel
• 19.7. Italy Acquired Orphan Blood Disease Market Analysis
  • 19.7.1. By Type
  • 19.7.2. By Disease Indication
  • 19.7.3. By Distribution Channel
• 19.8. France Acquired Orphan Blood Disease Market Analysis
  • 19.8.1. By Type
  • 19.8.2. By Disease Indication
  • 19.8.3. By Distribution Channel
• 19.9. U.K. Acquired Orphan Blood Disease Market Analysis
  • 19.9.1. By Type
  • 19.9.2. By Disease Indication
  • 19.9.3. By Distribution Channel
• 19.10. Spain Acquired Orphan Blood Disease Market Analysis
  • 19.10.1. By Type
  • 19.10.2. By Disease Indication
  • 19.10.3. By Distribution Channel
• 19.11.  BENELUX Acquired Orphan Blood Disease Market Analysis
  • 19.11.1. By Type
  • 19.11.2. By Disease Indication
  • 19.11.3. By Distribution Channel
• 19.12. Russia Acquired Orphan Blood Disease Market Analysis
  • 19.12.1. By Type
  • 19.12.2. By Disease Indication
  • 19.12.3. By Distribution Channel
• 19.13. China Acquired Orphan Blood Disease Market Analysis
  • 19.13.1. By Type
  • 19.13.2. By Disease Indication
  • 19.13.3. By Distribution Channel
• 19.14. Japan Acquired Orphan Blood Disease Market Analysis
  • 19.14.1. By Type
  • 19.14.2. By Disease Indication
  • 19.14.3. By Distribution Channel
• 19.15. S. Korea Acquired Orphan Blood Disease Market Analysis
  • 19.15.1. By Type
  • 19.15.2. By Disease Indication
  • 19.15.3. By Distribution Channel
• 19.16. India Acquired Orphan Blood Disease Market Analysis
  • 19.16.1. By Type
  • 19.16.2. By Disease Indication
  • 19.16.3. By Distribution Channel
• 19.17. ASEAN Acquired Orphan Blood Disease Market Analysis
  • 19.17.1. By Type
  • 19.17.2. By Disease Indication
  • 19.17.3. By Distribution Channel
• 19.18. Australia and New Zealand Acquired Orphan Blood Disease Market Analysis
  • 19.18.1. By Type
  • 19.18.2. By Disease Indication
  • 19.18.3. By Distribution Channel
• 19.19.  GCC Countries Acquired Orphan Blood Disease Market Analysis
  • 19.19.1. By Type
  • 19.19.2. By Disease Indication
  • 19.19.3. By Distribution Channel
• 19.20. Turkey Acquired Orphan Blood Disease Market Analysis
  • 19.20.1. By Type
  • 19.20.2. By Disease Indication
  • 19.20.3. By Distribution Channel
• 19.21. Northern Africa Acquired Orphan Blood Disease Market Analysis
  • 19.21.1. By Type
  • 19.21.2. By Disease Indication
  • 19.21.3. By Distribution Channel
• 19.22. South Africa Acquired Orphan Blood Disease Market Analysis
  • 19.22.1. By Type
  • 19.22.2. By Disease Indication
  • 19.22.3. By Distribution Channel

20. Market Structure Analysis

• 20.1. Market Analysis by Tier of Companies (Linear Alpha-Olefins)
• 20.2. Market Share Analysis of Top Players
• 20.3. Market Presence Analysis

21. Competition Analysis

• 21.1. Competition Dashboard
• 21.2. Competition Benchmarking
• 21.3. Competition Deep Dive
  • 21.3.1. Alexion Pharmaceuticals, Inc.
    • 21.3.1.1. Overview
    • 21.3.1.2. Product Portfolio
    • 21.3.1.3. Profitability by Market Segments (Product/Channel/Region)
    • 21.3.1.4. Sales Footprint
    • 21.3.1.5. Strategy Overview
  • 21.3.2. Amgen, Inc.
    • 21.3.2.1. Overview
    • 21.3.2.2. Product Portfolio
    • 21.3.2.3. Profitability by Market Segments (Product/Channel/Region)
    • 21.3.2.4. Sales Footprint
    • 21.3.2.5. Strategy Overview
  • 21.3.3. Celgene Corporation
    • 21.3.3.1. Overview
    • 21.3.3.2. Product Portfolio
    • 21.3.3.3. Profitability by Market Segments (Product/Channel/Region)
    • 21.3.3.4. Sales Footprint
    • 21.3.3.5. Strategy Overview
  • 21.3.4. Eli Lilly and Company
    • 21.3.4.1. Overview
    • 21.3.4.2. Product Portfolio
    • 21.3.4.3. Profitability by Market Segments (Product/Channel/Region)
    • 21.3.4.4. Sales Footprint
    • 21.3.4.5. Strategy Overview
  • 21.3.5. Sanofi S.A.
    • 21.3.5.1. Overview
    • 21.3.5.2. Product Portfolio
    • 21.3.5.3. Profitability by Market Segments (Product/Channel/Region)
    • 21.3.5.4. Sales Footprint
    • 21.3.5.5. Strategy Overview
  • 21.3.6. GlaxoSmithKline plc.
    • 21.3.6.1. Overview
    • 21.3.6.2. Product Portfolio
    • 21.3.6.3. Profitability by Market Segments (Product/Channel/Region)
    • 21.3.6.4. Sales Footprint
    • 21.3.6.5. Strategy Overview
  • 21.3.7. Cyclacel Pharmaceuticals, Inc.
    • 21.3.7.1. Overview
    • 21.3.7.2. Product Portfolio
    • 21.3.7.3. Profitability by Market Segments (Product/Channel/Region)
    • 21.3.7.4. Sales Footprint
    • 21.3.7.5. Strategy Overview
  • 21.3.8. Onconova Therapeutics, Inc.
    • 21.3.8.1. Overview
    • 21.3.8.2. Product Portfolio
    • 21.3.8.3. Profitability by Market Segments (Product/Channel/Region)
    • 21.3.8.4. Sales Footprint
    • 21.3.8.5. Strategy Overview
  • 21.3.9. Incyte Corporation
    • 21.3.9.1. Overview
    • 21.3.9.2. Product Portfolio
    • 21.3.9.3. Profitability by Market Segments (Product/Channel/Region)
    • 21.3.9.4. Sales Footprint
    • 21.3.9.5. Strategy Overview
  • 21.3.10. CTI BioPharma Corp.
    • 21.3.10.1. Overview
    • 21.3.10.2. Product Portfolio
    • 21.3.10.3. Profitability by Market Segments (Product/Channel/Region)
    • 21.3.10.4. Sales Footprint
    • 21.3.10.5. Strategy Overview

22. Assumptions and Acronyms Used

23. Research Methodology